Zydus Lifesciences New Jersey site passes USFDA inspection with no findings
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Zydus Lifesciences’ New Jersey office cleared a USFDA inspection of its pharmacovigilance and post‑marketing surveillance system from September 22‑25, 2026, with no observations.
- The inspection covered the company’s pharmacovigilance and post‑marketing surveillance system.
- It was conducted by the United States Food and Drug Administration.
- The inspection period ran from September 22 to September 25, 2026.
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Zydus Lifesciences' USA Office Clears USFDA Inspection With Nil Observations
Timeline
First reported by Free Press Journal on ; 2 articles from 2 outlets so far.
Who is covering this story
- Center (2): Free Press Journal, The Hindu BusinessLine